Why FATE? Fate Therapeutics, Inc. Analysis, Price & AI Insights | Whystock
FATE
$1.53+0.28 (+22.40%)
Market ClosedLast close May 1
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally.